Azelis stock faces Jefferies downgrade as leverage limits recovery

Jefferies downgraded Azelis from Buy to Hold on Wednesday, November 11, 2026, and cut its price target from 15 euros to 13 euros. Investing.com said analyst David Kerstens raised the assumed cost of capital to 10 percent from 9 percent and applied stricter return criteria.

Azelis stock traded at 12.00 euros on Lang & Schwarz at 17:40 CET on Thursday, November 12, 2026, 1.01 percent above the 11.88 euros cited in the latest report published at 10:49 CET the same day. This move since the previous report is separate from a daily exchange comparison.

Broker Turns More Cautious

Jefferies said a recovery toward moderate, volume-driven growth and gradually improving margins was already reflected in the shares after their strong advance. The brokerage expects the specialty-distribution sector to benefit from normalizing industrial conditions, but sees the fading inflation tailwind and a market still waiting for clearer volume growth.

Operating Recovery Meets Cash Pressure

The cautious rating comes despite stronger underlying third-quarter operations. Organic revenue growth reached 8.2 percent, while earnings before interest, taxes and amortization rose 15 percent to 114 million euros. Gross margin remained at 23.4 percent.

Cash conversion was weaker. Free cash flow fell 52 percent to 67 million euros as working-capital investment increased, including inventory to support recovering demand. Leverage stood at 3.5 times EBITDA, above the company's target of below 3 times.

Azelis also recognized a 350 million euro non-cash goodwill impairment related mainly to past acquisitions in the Americas. The charge reduced reported earnings and equity but did not directly affect cash flow, working capital or net debt.

2026 Target Remains Unchanged

Management continues to target positive organic adjusted EBITA growth for 2026. Medium-term ambitions include high-single-digit adjusted EBITA growth, earnings-per-share growth and a return on capital employed above 11.5 percent. Jefferies expects a 6 percent EBITA recovery and noted that Azelis does not expect to complete acquisitions this year while leverage and asking prices remain high.

European equity developments provide the wider market context through Current market reports.

Investors will focus next on fourth-quarter working-capital normalization, further EBITA progress and the path toward lower leverage. More news and analyses on Azelis stock.